Xing-Li Fu
Overview
Explore the profile of Xing-Li Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
411
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang G, Wang J, Zhi-Min Z, Xu X, Shi F, Fu X
Sci Prog
. 2023 Jan;
106(1):368504221147173.
PMID: 36718538
Colorectal cancer (CRC) can be resistant to platinum drugs, possibly through ferroptosis suppression, albeit the need for further work to completely understand this mechanism. This work aimed to sum up...
2.
Wang G, Wang J, Xu X, Shi F, Fu X
J Drug Target
. 2022 Apr;
30(8):819-832.
PMID: 35481396
Alterations in cellular energy metabolism, including glycolysis, glutamine and lipid metabolism that affects ferroptosis in the tumour microenvironment (TME), play a critical role in the development and progression of colorectal...
3.
Jing J, Fu X, Zhao W, Kong L
Clin Lab
. 2020 Jul;
66(7).
PMID: 32658432
Background: The red blood cell distribution width (RDW) was reported to be related to the severity of liver diseases, but its clinical significance in patients with hepatocellular carcinoma (HCC) remains...
4.
Wang G, Yu Y, Wang Y, Wang J, Guan R, Sun Y, et al.
J Cell Physiol
. 2019 Mar;
234(10):17023-17049.
PMID: 30888065
Increased risk of colorectal cancer (CRC) is associated with altered intestinal microbiota as well as short-chain fatty acids (SCFAs) reduction of output The energy source of colon cells relies mainly...
5.
Wang G, Wang J, Wang Y, Feng S, Jing G, Fu X
Artif Cells Nanomed Biotechnol
. 2019 Jan;
46(sup3):S180-S191.
PMID: 30691320
As the most aggressive and malignant glioma, glioblastoma multiforme (GBM) abnormally expresses genes that mediate glycolytic metabolism and tumour cell growth. In this study, we investigated myricetin incorporated nanoliposomes and...
6.
Wang G, Wang J, Yin P, Xu K, Wang Y, Shi F, et al.
J Cell Biochem
. 2018 Oct;
120(2):1106-1121.
PMID: 30362665
Alterations in cellular energy metabolism play critical roles in colorectal cancer (CRC). These alterations, which correlate to KRAS mutations, have been identified as energy metabolism signatures. This review summarizes the...
7.
Wang G, Wang J, Guan R, Sun Y, Shi F, Gao J, et al.
Curr Cancer Drug Targets
. 2018 Oct;
19(7):534-550.
PMID: 30360743
Colorectal cancer is a heterogeneous group of diseases that result from the accumulation of different sets of genomic alterations, together with epigenomic alterations, and it is influenced by tumor-host interactions,...
8.
Wang G, Wang J, Yin P, Xu K, Wang Y, Shi F, et al.
J Cell Physiol
. 2018 Oct;
234(5):5601-5612.
PMID: 30341899
Alterations in cellular energy metabolism play a critical role in colorectal cancer (CRC), which has been identified as the definition of consensus molecular subtypes (CMSs), and CMS3 tumors exhibit energy...
9.
Wang G, Wang J, Yin P, Xu K, Wang Y, Shi F, et al.
J Cell Physiol
. 2018 Aug;
234(1):348-368.
PMID: 30069931
Colorectal cancer (CRC) is a heterogeneous group of diseases that are the result of abnormal glucose metabolism alterations with high lactate production by pyruvate to lactate conversion, which remodels acidosis...
10.
Gang W, Wang J, Guan R, Yan S, Shi F, Zhang J, et al.
Cancer Med
. 2018 Apr;
7(5):1578-1603.
PMID: 29658188
Assessing the CRC subtypes that can predict the outcome of colorectal cancer (CRC) in patients with immunogenicity seems to be a promising strategy to develop new drugs that target the...